All Stories

  1. The NLR member CIITA: Master controller of adaptive and intrinsic immunity and unexpected tool in cancer immunotherapy

    Article • Biomedical Journal, October 2023, Elsevier

    Roberto Accolla

  2. HTLV-1 Infection and Pathogenesis: New Insights from Cellular and Animal Models

    Article • International Journal of Molecular Sciences, July 2021, MDPI AG

    Roberto Accolla

  3. HTLV-1 Infection and Adult T Cell Leukemia Mechanisms of Oncogenesis and Alteration of Immunity

    Article • January 2021, Vide Leaf

    Roberto Accolla

  4. CIITA-Transduced Glioblastoma Cells Uncover a Rich Repertoire of Clinically Relevant Tumor-Associated HLA-II Antigens

    Article • Molecular & Cellular Proteomics, January 2021, Elsevier

    Roberto Accolla

  5. Epigenetic silencing of HTLV-1 expression by the HBZ RNA through interference with the basal transcription machinery

    Article • Blood Advances, November 2020, American Society of Hematology

    Roberto Accolla

  6. Editorial: Novel Strategies for Anti-Tumor Vaccines

    Article • Frontiers in Immunology, January 2020, Frontiers

    Roberto Accolla

  7. Novel Strategies of Anti-Tumor Vaccines

    Article • January 2020, Frontiers

    Roberto Accolla

  8. Restriction factors in human retrovirus infections and the unprecedented case of CIITA as link of intrinsic and adaptive immunity against HTLV-1

    Article • Retrovirology, November 2019, Springer Science + Business Media

    Roberto Accolla

  9. CIITA-Driven MHC Class II Expressing Tumor Cells as Antigen Presenting Cell Performers: Toward the Construction of an Optimal Anti-tumor Vaccine

    Article • Frontiers in Immunology, July 2019, Frontiers

    Roberto Accolla

  10. CIITA-related block of HLA class II expression, upregulation of HLA class I, and heterogeneous expression of immune checkpoints in hepatocarcinomas: implications for new therapeutic approaches

    Article • OncoImmunology, November 2018, Taylor & Francis

    Roberto Accolla

  11. B-104 Cancer vaccine: Tumor immunology meets...Immunology

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2018, Wolters Kluwer Health

    Roberto Accolla

  12. HTLV-1 HBZ Viral Protein: A Key Player in HTLV-1 Mediated Diseases

    Article • Frontiers in Microbiology, December 2017, Frontiers

    Roberto Accolla

  13. Tripartite Motif 22 and Class II Transactivator Restriction Factors: Unveiling Their Concerted Action against Retroviruses

    Article • Frontiers in Immunology, October 2017, Frontiers

    Roberto Accolla

  14. New concept in Immunology

    Article • OncoImmunology, July 2017, Taylor & Francis

    Roberto Accolla

  15. The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-κB by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein

    Article • Journal of Virology, January 2016, ASM Journals

    Roberto Accolla

  16. Abstract B047: Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment

    Article • Cancer Immunology Research, January 2016, American Association for Cancer Research (AACR)

    Roberto Accolla

  17. The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1

    Article • Retrovirology, August 2015, Springer Science + Business Media

    Roberto Accolla

  18. Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL

    Article • Retrovirology, August 2015, Springer Science + Business Media

    Roberto Accolla

  19. Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL

    Article • Retrovirology, August 2015, Springer Science + Business Media

    Roberto Accolla

  20. Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL

    Article • Retrovirology, July 2015, Springer Science + Business Media

    Roberto Accolla

  21. Class II Transactivator-Induced MHC Class II Expression in Pancreatic Cancer Cells Leads to Tumor Rejection and a Specific Antitumor Memory Response

    Article • Pancreas, October 2014, Wolters Kluwer Health

    Roberto Accolla

  22. Boosting the MHC Class II-Restricted Tumor Antigen Presentation to CD4+ T Helper Cells: A Critical Issue for Triggering Protective Immunity and Re-Orienting the Tumor Microenvironment Toward an Anti-Tumor State

    Article • Frontiers in Oncology, January 2014, Frontiers

    Roberto Accolla

  23. Investigating Human T Cell Lymphotropic Retrovirus (HTLV) Tax Function with Molecular and Immunophenotypic Techniques

    Article • January 2014, Springer Science + Business Media

    Roberto Accolla

  24. The MHC Class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation

    Article • Retrovirology, January 2014, Springer Science + Business Media

    Roberto Accolla

  25. P105 The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2013, Wolters Kluwer Health

    Roberto Accolla

  26. P104 Suitable Antigen Availability

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, April 2013, Wolters Kluwer Health

    Roberto Accolla

  27. The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators

    Article • Frontiers in Microbiology, January 2013, Frontiers

    Roberto Accolla

  28. Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy

    Article • Journal of Neuroimmune Pharmacology, December 2012, Springer Science + Business Media

    Roberto Accolla

  29. Down syndrome, autoimmunity and T regulatory cells

    Article • Clinical & Experimental Immunology, August 2012, Oxford University Press (OUP)

    Roberto Accolla

  30. Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines

    Article • Journal of Translational Medicine, July 2012, Springer Science + Business Media

    Roberto Accolla

  31. Typing of a Polymorphic Human Gene Conferring Susceptibility to Insulin-Dependent Diabetes Mellitus by Picosecond-Resolved FRET on Non-Purified/Non-Amplified Genomic DNA

    Article • DNA Research, June 2012, Oxford University Press (OUP)

    Roberto Accolla

  32. Dendritic Cell Editing by Activated Natural Killer Cells Results in a More Protective Cancer-Specific Immune Response

    Article • PLoS ONE, June 2012, PLOS

    Dr Laura Chiossone, Roberto Accolla

  33. Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes

    Article • May 2012, SPIE

    Roberto Accolla

  34. Major Histocompatibility Complex Class II Transactivator CIITA Is a Viral Restriction Factor That Targets Human T-Cell Lymphotropic Virus Type 1 Tax-1 Function and Inhibits Viral Replication

    Article • Journal of Virology, August 2011, ASM Journals

    Roberto Accolla

  35. Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication

    Article • Journal of Translational Medicine, July 2011, Springer Science + Business Media

    Roberto Accolla

  36. MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to, and affecting Tax-2 intracellular localization

    Article • Retrovirology, June 2011, Springer Science + Business Media

    Roberto Accolla

  37. New Strategies of Mammary Cancer Vaccination

    Article • The Breast Journal, September 2010, Hindawi Publishing Corporation

    Roberto Accolla

  38. CIITA‐driven MHC‐II positive tumor cells: Preventive vaccines and superior generators of antitumor CD4+ T lymphocytes for immunotherapy

    Article • International Journal of Cancer, August 2010, Wiley

    Roberto Accolla

  39. Therapy‐induced antitumor vaccination in neuroblastomas by the combined targeting of IL‐2 and TNFα

    Article • International Journal of Cancer, April 2010, Wiley

    Roberto Accolla

  40. Irradiated CIITA-positive mammary adenocarcinoma cells act as a potent anti-tumor-preventive vaccine by inducing tumor-specific CD4+ T cell priming and CD8+ T cell effector functions

    Article • International Immunology, April 2009, Oxford University Press (OUP)

    Roberto Accolla

  41. NK cells provide helper signal for CD8+ T cells by inducing the expression of membrane-bound IL-15 on DCs

    Article • International Immunology, March 2009, Oxford University Press (OUP)

    Roberto Accolla

  42. Unsung Hero Robert C. Gallo

    Article • Science, January 2009, American Association for the Advancement of Science

    Dr Maria Lina Tornesello , Donato Zipeto, Roberto Accolla

  43. Methylation of CIITA promoter IV causes loss of HLA-II inducibility by IFN-  in promyelocytic cells

    Article • International Immunology, September 2008, Oxford University Press (OUP)

    Roberto Accolla

  44. Experimental therapeutic approaches to adenocarcinoma: The potential of tumor cells engineered to express MHC class II molecules combined with naked DNA interleukin-12 gene transfer

    Article • Surgical Oncology, December 2007, Elsevier

    Roberto Accolla

  45. Therapy-induced antitumor vaccination by targeting tumor necrosis factor-α to tumor vessels in combination with melphalan

    Article • European Journal of Immunology, December 2007, Wiley

    Roberto Accolla

  46. A dual defensive role of CIITA against retroviral infections

    Article • Retrovirology, December 2006, Springer Science + Business Media

    Roberto Accolla

  47. Inhibition of human T cell leukemia virus type 2 replication by the suppressive action of class II transactivator and nuclear factor Y

    Article • Proceedings of the National Academy of Sciences, August 2006, Proceedings of the National Academy of Sciences

    Roberto Accolla

  48. Host Defense Mechanisms against Pathogens

    Article • Surgical Infections, July 2006, Mary Ann Liebert Inc

    Roberto Accolla

  49. CIITA-Induced MHC Class II Expression in Mammary Adenocarcinoma Leads to a Th1 Polarization of the Tumor Microenvironment, Tumor Rejection, and Specific Antitumor Memory

    Article • Clinical Cancer Research, June 2006, American Association for Cancer Research (AACR)

    Roberto Accolla

  50. Targeted Delivery of Tumor Necrosis Factor-α to Tumor Vessels Induces a Therapeutic T Cell–Mediated Immune Response that Protects the Host Against Syngeneic Tumors of Different Histologic Origin

    Article • Clinical Cancer Research, April 2006, American Association for Cancer Research (AACR)

    Roberto Accolla

  51. The MHC Class II Transactivator (CIITA): A "Physiologic" Drug Against HIV-1 Replication

    Article • Retrovirology, December 2005, Springer Science + Business Media

    Roberto Accolla

  52. Human Naive CD4 T-Cell Clones Specific for HIV Envelope Persist for Years In Vivo in the Absence of Antigenic Challenge

    Article • JAIDS Journal of Acquired Immune Deficiency Syndromes, October 2005, Wolters Kluwer Health

    Roberto Accolla

  53. MHC immunoevasins: protecting the pathogen reservoir in infection

    Article • Tissue Antigens, June 2005, Wiley

    Roberto Accolla

  54. The MHC class?II transactivator (CIITA) mRNA stability is critical for the HLA class?II gene expression in myelomonocytic cells

    Article • European Journal of Immunology, February 2005, Wiley

    Roberto Accolla

  55. Article • BMC Microbiology, January 2005, Springer Science + Business Media

    Roberto Accolla

  56. Nonantigen specific CD8+ T suppressor lymphocytes originate from CD8+CD28− T cells and inhibit both T-Cell proliferation and CTL function

    Article • Human Immunology, February 2004, Elsevier

    Roberto Accolla

  57. The MHC class II transcriptional activator (CIITA) inhibits HTLV-2 viral replication by blocking the function of the viral transactivator Tax-2

    Article • Blood, February 2004, American Society of Hematology

    Roberto Accolla

  58. Different levels of control prevent interferon-γ-inducible HLA-class II expression in human neuroblastoma cells

    Article • Oncogene, October 2003, Springer Science + Business Media

    Roberto Accolla

  59. Tumor rejection by gene transfer of the MHC class II transactivator in murine mammary adenocarcinoma cells

    Article • European Journal of Immunology, April 2003, Wiley

    Roberto Accolla

  60. The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication

    Article • European Journal of Immunology, October 2002, Wiley

    Roberto Accolla

  61. Block of Stat-1 activation in macrophages phagocytosing bacteria causes reduced transcription of CIITA and consequent impaired antigen presentation

    Article • European Journal of Immunology, May 2002, Wiley

    Roberto Accolla

  62. Preservation of clonal heterogeneity of the Pneumocystis carinii -specific CD4 T cell repertoire in HIV infected, asymptomatic individuals

    Article • Clinical & Experimental Immunology, April 2002, Wiley

    Dr Emanuele Pontali, Roberto Accolla

  63. Analysis of the antigen specific T cell repertoires in HIV infection

    Article • Immunology Letters, November 2001, Elsevier

    Professor Arianna Loregian, Dr Emanuele Pontali, Roberto Accolla

  64. The MHC class II transactivator: prey and hunter in infectious diseases

    Article • Trends in Immunology, October 2001, Elsevier

    Roberto Accolla

  65. Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR

    Article • European Journal of Immunology, April 2000, Wiley

    Roberto Accolla

  66. HIV-1 Tat mutants in the cysteine-rich region downregulate HLA class II expression in T lymphocytic and macrophage cell lines

    Article • European Journal of Immunology, January 2000, Wiley

    Roberto Accolla

  67. Distinct regulation of HLA class II and class I cell surface expression in the THP-1 macrophage cell line after bacterial phagocytosis

    Article • European Journal of Immunology, February 1999, Wiley

    Roberto Accolla

  68. HLA and MHC: Genes Molecules and function

    Article • Immunology Today, April 1997, Elsevier

    Roberto Accolla

  69. APC gene mutations and allelic losses in sporadic ampullary tumours: Evidence of genetic difference from tumours associated with familial adenomatous polyposis

    Article • International Journal of Cancer, November 1996, Wiley

    Roberto Accolla

  70. Active suppression of the class II transactivator-encodingAIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells

    Article • European Journal of Immunology, October 1996, Wiley

    Roberto Accolla

  71. Divergent evolution in the mechanisms controlling major histocompatibility complex class II gene transcription in mouse and human

    Article • European Journal of Immunology, January 1996, Wiley

    Roberto Accolla

  72. Transcriptional regulation of MHC class II genes

    Article • International Journal of Clinical & Laboratory Research, June 1995, Springer Science + Business Media

    Roberto Accolla

  73. MHC: orchestrating the immune response

    Article • Immunology Today, January 1995, Elsevier

    Roberto Accolla

  74. In vivo modification of major histocompatibility complex class II DRA promoter occupancy mediated by the AIR‐1 trans‐activator

    Article • European Journal of Immunology, October 1994, Wiley

    Roberto Accolla

  75. ras-family gene mutations in neoplasia of the ampulla of vater

    Article • International Journal of Cancer, October 1994, Wiley

    Roberto Accolla

  76. Evidence for a trans-acting activator function regulating the expression of the human CD5 antigen

    Article • Immunogenetics, July 1994, Springer Science + Business Media

    Roberto Accolla

  77. The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for insulin-dependent diabetes mellitus

    Article • Molecular Immunology, April 1994, Elsevier

    Roberto Accolla

  78. Physiologic target of the Air-1 trans-activator revealed by stable transfection assay

    Article • Immunogenetics, January 1994, Springer Science + Business Media

    Roberto Accolla

  79. Role of the HLA-DQ Genotype in IDDM Susceptibility

    Article • January 1994, Springer Science + Business Media

    Roberto Accolla

  80. Detection of human chromosomes in somatic cell hybrids by PCR analysis

    Article • Cytogenetic and Genome Research, January 1993, Karger Publishers

    Roberto Accolla

  81. HLA-DQB1 typing of north east Italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-enzyme immunoassay (DEIA)

    Article • Molecular Immunology, January 1993, Elsevier

    Roberto Accolla

  82. Constitutive expression of CD69 in interspecies T-cell hybrids and locus assignment to human chromosome 12

    Article • Immunogenetics, June 1992, Springer Science + Business Media

    Roberto Accolla

  83. The molecular biology of MHC genes

    Article • Immunology Today, April 1991, Elsevier

    Roberto Accolla

  84. Structural analysis of the CD69 early activation antigen by two monoclonal antibodies directed to different epitopes

    Article • Molecular Immunology, January 1991, Elsevier

    Roberto Accolla

  85. Superinfection by Epstein-Barr virus of a subset of Raji cells is independent of HLA class-II antigens

    Article • International Journal of Cancer, May 1990, Wiley

    Roberto Accolla

  86. A family of trans-acting factors with distinct regulatory functions control expression of MHC class II genes

    Article • Immunologic Research, March 1990, Springer Science + Business Media

    Roberto Accolla

  87. Different staphylococcal enterotoxins bind preferentially to distinct major histocompatibility complex class ii isotypes

    Article • European Journal of Immunology, November 1989, Wiley

    Roberto Accolla

  88. Heterogeneity of lymphokyne-activated killer (LAK) populations at the clonal level: Both NK and CD3+, CD4−, CD8− clones efficiently mediate tumor cell killing

    Article • Clinical Immunology and Immunopathology, October 1988, Elsevier

    Roberto Accolla

  89. Active suppression of major histocompatibility complex class II gene expression during differentiation from B cells to plasma cells.

    Article • Proceedings of the National Academy of Sciences, April 1988, Proceedings of the National Academy of Sciences

    Roberto Accolla

  90. Molecular genotyping of the HLA-DQ ? gene region

    Article • Immunogenetics, January 1988, Springer Science + Business Media

    Roberto Accolla

  91. The genes for lumor necrosis factor (TNF-alpha) and lymphotoxin (TNF-beta) are tandemly arranged on chromosome 17 of the mouse

    Article • Nucleic Acids Research, January 1986, Oxford University Press (OUP)

    Roberto Accolla

  92. Ia-negative B-cell variants reveal a coordinate regulation in the transcription of the HLA Class II gene family

    Article • Immunogenetics, January 1984, Springer Science + Business Media

    Roberto Accolla

  93. Biochemical aspects of human Ia molecules

    Article • Human Immunology, September 1983, Elsevier

    Roberto Accolla

  94. The importance of cross-reactions between species: Mouse allo-anti-Ia monoclonal antibodies as a powerful tool to define human Ia subsets

    Article • Human Immunology, September 1983, Elsevier

    Roberto Accolla

  95. Distinct HLA‐DR epitopes and distinct families of HLA‐DR molecules defined by 15 monoclonal antibodies (mAb) either anti‐DR or allo‐anti‐Iak crossreacting with human DR molecule. I. Cross‐inhibition studies of mAb cell surface fixation and d...

    Article • European Journal of Immunology, January 1983, Wiley

    Roberto Accolla

  96. Isolation of distinct cDNA clones encoding HLA-DR beta chains by use of an expression assay.

    Article • Proceedings of the National Academy of Sciences, December 1982, Proceedings of the National Academy of Sciences

    Roberto Accolla

  97. Isolation of cDNA clones encoding HLA-DR alpha chains.

    Article • Proceedings of the National Academy of Sciences, November 1982, Proceedings of the National Academy of Sciences

    Roberto Accolla

  98. Sandwich enzyme immunoassay using three monoclonal antibodies against different epitopes of carcinoembryonic antigen (CEA)

    Article • Immunology Letters, August 1982, Elsevier

    Roberto Accolla

  99. Monoclonal antibodies against carcinoembryonic antigen (CEA) used in a solid-phase enzyme immunoassay. First clinical results

    Article • Journal of Immunological Methods, March 1982, Elsevier

    Roberto Accolla

  100. Functional Analysis of Human Ia Subsets

    Article • January 1982, Elsevier

    Roberto Accolla

  101. Biochemical Analysis of Human HLA-DR Molecules

    Article • January 1982, Elsevier

    Roberto Accolla

  102. Monoclonal Antibodies as a Tool to Detect Melanoma-Associated Antigens

    Article • January 1982, Springer Science + Business Media

    Roberto Accolla

  103. Use of radiolabelled monoclonal anti-CEA antibodies for the detection of human carcinomas by external photoscanning and tomoscintigraphy

    Article • Immunology Today, December 1981, Elsevier

    Roberto Accolla

  104. Subsets of human Ia-like molecules defined by monoclonal antibodies

    Article • Molecular Immunology, May 1981, Elsevier

    Roberto Accolla

  105. Binding of one monoclonal antibody to human Ia molecules can be enhanced by a second monoclonal antibody

    Article • European Journal of Immunology, January 1981, Wiley

    Professor Rosa Sorrentino, Roberto Accolla

  106. Antibody‐mediated activation of a deletion‐mutant β‐galactosidase defective in the α region

    Article • FEBS Letters, September 1976, Wiley

    Roberto Accolla